Exciting Upcoming Business Update from SIGA Technologies
NEW YORK, July 29, 2025 - SIGA Technologies, Inc. (NASDAQ: SIGA), a leader in the pharmaceutical sector, has recently revealed plans for an upcoming business update call. Scheduled for 4:30 P.M. ET on August 5, 2025, this event promises to shed light on compelling advancements within the company. Diem Nguyen, the Chief Executive Officer, along with Daniel Luckshire, the Chief Financial Officer, will participate in this informative session.
Accessing the Business Update Call
The live broadcast of the call will be available for all interested parties, which attendees can access through the Investor Relations section of the company’s website. To ensure a seamless experience, it is suggested to log in around 5-10 minutes before the event begins.
For those who wish to join the call, dial-in numbers are available: domestic callers can reach out through 1-800-717-1738, while international participants can connect via 1-646-307-1865. This ensures that all stakeholders have the opportunity to engage with the latest insights.
Replay Options Available
To cater to varying schedules, a replay of the call will be available for two weeks following the event. Domestic callers can use 1-844-512-2921, and international callers can access the replay by dialing 1-412-317-6671, utilizing Conference ID: 1130215 for ease of access. Furthermore, an archived version of the webcast will be posted on the company’s website under the Investor Relations section.
About SIGA Technologies
SIGA Technologies is firmly committed to advancing public health by developing groundbreaking medicines aimed at treating infectious diseases. The company holds a significant focus on orthopoxviruses, striving to safeguard global health against severe infectious threats, whether they arise naturally or through man-made incidents. Through proactive partnerships with governmental bodies and public health organizations, SIGA is instrumental in crafting essential countermeasures to combat these threats.
The company’s flagship antiviral product, TPOXX (tecovirimat), has earned approval in both the U.S. and Canada for smallpox treatment and has received authorization in Europe, the UK, and Japan for additional conditions including mpox (monkeypox), cowpox, and complications arising from vaccinations. These developments highlight SIGA's pivotal role in public health.
Contact Information for SIGA Technologies
For inquiries or further information, Suzanne Harnett is available via email at sharnett@siga.com.
Additionally, for investor relations, Jennifer Drew-Bear of Edison Group can also be contacted at Jdrew-bear@edisongroup.com, and for media inquiries, Holly Stevens from CG Life can be reached at hstevens@cglife.com.
Frequently Asked Questions
What is the date and time of the business update call?
The business update call is scheduled for August 5, 2025, at 4:30 P.M. ET.
Who will participate in the call?
Diem Nguyen, CEO, and Daniel Luckshire, CFO of SIGA Technologies, will host the call.
How can I access the live update call?
The call can be accessed through the company’s website in the Investor Relations section or by dialing the provided numbers for participation.
Will a replay of the call be available?
Yes, a replay will be available for two weeks following the call, with specific dial-in numbers provided for access.
What is the focus of SIGA Technologies?
SIGA is dedicated to developing innovative solutions for infectious diseases, primarily focusing on treating and preventing threats from orthopoxviruses.
